Overview

A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed stage 3B light chain (AL) amyloidosis.
Phase:
Phase 2
Details
Lead Sponsor:
European Myeloma Network
Collaborator:
Janssen Pharmaceutica
Treatments:
Antibodies, Monoclonal
BB 1101
Bortezomib
Daratumumab
Dexamethasone
Dexamethasone acetate